NCT01763931View on ClinicalTrials.gov

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 1, 2016

Study Completion Date

April 1, 2016

Conditions
Breast Cancer
Interventions
DRUG

Digoxin

Digoxin once daily for 2 weeks prior to definitive breast surgery.

Trial Locations (1)

21231

Kimmel Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01763931 - DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer | Biotech Hunter | Biotech Hunter